Tucotuzumab
Modify Date: 2025-08-29 12:39:25
Tucotuzumab structure
|
Common Name | Tucotuzumab | ||
|---|---|---|---|---|
| CAS Number | 339986-90-2 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of TucotuzumabTucotuzumab (Anti-EPCAM Recombinant Antibody) is a protein composed of an IgG1 monoclonal antibody specific for the human Epithelial Cell Adhesion Molecule (EpCAM) antigen, linked to two molecules of IL-2. Tucotuzumab is an immunosuppressant and antineoplastic agent[1]. |
| Name | Tucotuzumab |
|---|
| Description | Tucotuzumab (Anti-EPCAM Recombinant Antibody) is a protein composed of an IgG1 monoclonal antibody specific for the human Epithelial Cell Adhesion Molecule (EpCAM) antigen, linked to two molecules of IL-2. Tucotuzumab is an immunosuppressant and antineoplastic agent[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Tucotuzumab 靶向肿瘤并通过 IL-2 应答性免疫细胞刺激抗肿瘤免疫反应，以及通过其 Fc 受体刺激免疫细胞[1]。 |
| In Vivo | Tucotuzumab (75 μg; 瘤内注射; 每日 5 次，每次15 μg (总剂量 75 μg)，各用50 μL PBS; 在第 10 天和第 14 天)，肿瘤生长抑制显著增强，生存率提高[1]。 Animal Model: Female Balb/c mice bearing CT26-KS colon adenocarcinoma[1] Dosage: 75 μg Administration: Intratumoral injection; 5 daily of 15 μg (total dose of 75 μg), each in 50 μL PBS; on days 10 and 14 Result: Resulted in significantly greater tumor growth suppression and enhanced survival. |
| References |
| No Any Chemical & Physical Properties |